Semaglutide versus tirzepatide is usually sold as a contest over the bigger weight-loss number. That is not how an individual medication decision gets made.
I care about the comparison because people show up asking which one to pick, and a blog is the wrong person to answer. History, other medications, coverage, tolerability, and the prescriber's judgment sit above any headline. What I can do is tell you what the two drugs are, what is worth noticing while you are on one, and what to bring back to clinic.
There is no universal winner. There is a better conversation.
The Educational Difference, Not A Verdict
Semaglutide acts on the GLP-1 receptor. Tirzepatide acts on GLP-1 and GIP. Trial programs and clinic experience often show different average weight-change and nausea patterns, and those averages still fail as a personal forecast. Your version of “better” might be fewer GI days, better coverage, or a pace your clinician is willing to supervise.
Use a comparison article to prepare questions. Use the prescribing clinician to choose, monitor, and adjust.
Questions Only A Prescriber Can Answer
- Is this class appropriate for me at all?
- Which product, dose schedule, and follow-up cadence fit my history?
- What side effects mean call today versus mention at the next visit?
- How should other medications, gallbladder history, or GI disease change the plan?
Unapproved or compounded versions of these drugs have their own FDA-published concerns. That is not a DIY sourcing problem. It is a reason to stay inside legitimate care. See the FDA page on unapproved GLP-1 drugs used for weight loss. As of 2025–2026, FDA has also said national shortages that once widened compounding pathways have resolved, and it has proposed tighter limits on large-scale compounding of these ingredients. That is a clinic-and-pharmacy issue, not a sourcing tip.
What Is Worth Tracking Between Visits
The scale will be loud. It is still a weak scorecard by itself. Two people can lose the same weight and finish in very different shape. That is why I keep pointing at protein, lifting, symptoms, and composition instead of crowning a drug.
| Signal | Why it belongs in the visit | What it is not |
|---|---|---|
| Weight trend | Shows pace the clinician can judge | Proof you are losing the right tissue |
| Protein and lifting | Shows whether muscle had a chance | A license to change the dose yourself |
| GI and other symptoms | Pattern the prescriber can act on | Something to titrate from Reddit |
| How clothes, strength, energy feel | Context the scale hides | A diagnosis |
The longer playbook is in how to keep muscle on a GLP-1. Early weeks have their own shape in week 3 on tirzepatide. None of that replaces the person who wrote the prescription.
Mallet's GLP-1 tools are built to make the next clinician visit more specific: food noise, protein, lifting, and a Muscle Preservation Score the scale cannot compute. They are not built to pick your medication. Get early access →
This Week
If you are already on one of these drugs, log three days of protein, one strength session, and the symptoms you would actually mention out loud. Take that to the next visit. If you are still choosing, ask the prescriber the questions above instead of picking a winner from a chart.
Education only. Not medical advice and not a recommendation of one medication over another. Medication choice, dosing, and monitoring belong with a licensed clinician.